CN106068127B - 蛋白质的硫醚缀合方法 - Google Patents

蛋白质的硫醚缀合方法 Download PDF

Info

Publication number
CN106068127B
CN106068127B CN201480068335.5A CN201480068335A CN106068127B CN 106068127 B CN106068127 B CN 106068127B CN 201480068335 A CN201480068335 A CN 201480068335A CN 106068127 B CN106068127 B CN 106068127B
Authority
CN
China
Prior art keywords
protein
chemical moiety
conjugation
solution
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480068335.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN106068127A (zh
Inventor
C.S.亨內彻
T.B.汉森
E.B.汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk Health Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care AG filed Critical Novo Nordisk Health Care AG
Publication of CN106068127A publication Critical patent/CN106068127A/zh
Application granted granted Critical
Publication of CN106068127B publication Critical patent/CN106068127B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480068335.5A 2013-12-13 2014-12-15 蛋白质的硫醚缀合方法 Active CN106068127B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13197150 2013-12-13
EP13197150.9 2013-12-13
PCT/EP2014/077777 WO2015086853A1 (en) 2013-12-13 2014-12-15 Method for thioether conjugation of proteins

Publications (2)

Publication Number Publication Date
CN106068127A CN106068127A (zh) 2016-11-02
CN106068127B true CN106068127B (zh) 2020-06-19

Family

ID=49765887

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480068335.5A Active CN106068127B (zh) 2013-12-13 2014-12-15 蛋白质的硫醚缀合方法

Country Status (6)

Country Link
US (1) US11219690B2 (https=)
EP (1) EP3079722B1 (https=)
JP (1) JP6603662B2 (https=)
CN (1) CN106068127B (https=)
ES (1) ES2869309T3 (https=)
WO (1) WO2015086853A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA127495C2 (uk) 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
IL313587A (en) 2017-01-17 2024-08-01 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
EA201992502A1 (ru) 2017-06-20 2020-04-22 Эмджен Инк. Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
EP3642238A1 (en) 2017-06-21 2020-04-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
LT3661562T (lt) * 2017-08-04 2024-10-25 Amgen Inc. Cys-mab konjugavimo būdas

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1210400C (zh) * 1999-01-14 2005-07-13 博尔德生物技术公司 制备含游离半胱氨酸残基的蛋白质的方法
WO2006134173A2 (en) * 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
CN101212984A (zh) * 2005-07-06 2008-07-02 Ucb医药有限公司 连接效应分子与蛋白质的方法
CN103002918A (zh) * 2010-01-22 2013-03-27 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
CN103087183A (zh) * 2013-01-17 2013-05-08 南京邮电大学 一种光激发蛋白质中二硫键还原得到自由巯基的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2004101597A2 (en) 2003-05-13 2004-11-25 Frutarom Ltd. Methods for the reduction of disulfide bonds
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
WO2007109475A2 (en) * 2006-03-16 2007-09-27 Bracco Imaging S.P.A. Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
JP5703020B2 (ja) 2007-08-24 2015-04-15 ノボ ノルディスク ヘルス ケア アーゲー タンパク質を選択的に修飾するための組成物と方法
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
ES2582590T3 (es) 2010-02-16 2016-09-13 Novo Nordisk A/S Método de purificación
EP2595661A1 (en) 2010-07-22 2013-05-29 Novo Nordisk Health Care AG Growth hormone conjugates
JP2014520094A (ja) 2011-05-27 2014-08-21 バクスター・インターナショナル・インコーポレイテッド 増加した半減期を有する治療用タンパク質およびそれを調製する方法
HUE035685T2 (en) * 2011-11-02 2018-05-28 Hoffmann La Roche Overload and elute chromatography

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1210400C (zh) * 1999-01-14 2005-07-13 博尔德生物技术公司 制备含游离半胱氨酸残基的蛋白质的方法
WO2006134173A2 (en) * 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
CN101212984A (zh) * 2005-07-06 2008-07-02 Ucb医药有限公司 连接效应分子与蛋白质的方法
CN103002918A (zh) * 2010-01-22 2013-03-27 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
CN103087183A (zh) * 2013-01-17 2013-05-08 南京邮电大学 一种光激发蛋白质中二硫键还原得到自由巯基的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Technology trends in antibody purification";Pete Gagnon;《 J. Chromatogr. A》;20111020;第1221卷;第57-70页 *

Also Published As

Publication number Publication date
WO2015086853A1 (en) 2015-06-18
CN106068127A (zh) 2016-11-02
US11219690B2 (en) 2022-01-11
EP3079722A1 (en) 2016-10-19
US20160303248A1 (en) 2016-10-20
EP3079722B1 (en) 2021-03-24
JP6603662B2 (ja) 2019-11-06
JP2017501148A (ja) 2017-01-12
ES2869309T3 (es) 2021-10-25

Similar Documents

Publication Publication Date Title
CN106068127B (zh) 蛋白质的硫醚缀合方法
FI113272B (fi) Parannettu proteiinien laskostamismenetelmä
Liebner et al. Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra
Zhang et al. Chromatographic separation of hemoglobin variants using robust molecularly imprinted polymers
AU735480B2 (en) A process for preparing human proinsulin
CN102234310B (zh) 一种聚乙二醇修饰蛋白的分离纯化方法
ES2751735T3 (es) Métodos de replegado de proteínas a elevado pH
ES2813501T3 (es) Métodos de replegado de proteínas basados en filtración de flujo tangencial
CN104926924A (zh) 一种利用手性锍盐侧链稳定多肽α-螺旋二级结构的方法
CN101173006B (zh) 一种重组人胰岛素的制备方法
JP2017501148A5 (https=)
CN108610415A (zh) 一种抗体复合物的制备方法
JP2005506319A (ja) 融合タンパク質から目的タンパク質を分離する方法。
CN100387614C (zh) 包涵体蛋白复性并同时纯化的方法
CN114891086B (zh) 一种生物素标记的gdf15的复性方法
CN106632588A (zh) 一种聚乙二醇修饰蛋白的纯化工艺
CN105473610A (zh) 用于pth的纯化方法
CN104945498A (zh) 长效化PEG-rExendin-4改构体偶联物的制备
WO2018193033A1 (en) Methods of purification of albumin fusion proteins
Carter et al. Design of self-assembling protein-polymer conjugates
JP2022511951A5 (https=)
CN102585012B (zh) 一种石斑鱼α干扰素衍生物的制备方法与应用
EP2551263B1 (en) Thiosulfonate compound, reversibly cationizing agent for proteins and/or peptides, and method for solubilization
CN102807599A (zh) 一种纯化包涵体蛋白并复性的方法
CN121824729A (zh) 一种基于tcep的重组胰岛素原包涵体变复性方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant